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Abstract
Atrial fibrillation (AF) is associated with an increased risk of stroke compared
with the general population. It is anticipated that by 2030 an estimated 14–17
million patients will be diagnosed with this most prevalent arrhythmia within the
European Union. AF-related stroke confers a higher mortality and morbidity
risk, and thus early detection and assessment for the initiation of effective
stroke prevention with oral anticoagulation (OAC) is crucial. Recent guidelines
point to the use of non-vitamin K antagonist OACs (NOACs) where appropriate
in stroke prevention of patients with non-valvular AF. At present, there are four
NOACS available, with no direct head-to-head comparisons to suggest the
superiority of one drug over another.
Simple and practical risk assessment tools have evolved over the years to
facilitate stroke and bleeding risk assessment in busy clinics and wards to aid
decision-making. At present, the CHA DS VASc (congestive heart failure,
hypertension, age 65–74/>75, diabetes mellitus, stroke/transient ischemic
attack/thromboembolism, vascular disease, female sex) score is recommended
by many international guidelines as a simple and practical method of assessing
stroke risk in such patients. Alongside this, use of the HAS BLED (hypertension
systolic blood pressure >160 mmHg, abnormal liver/renal function [with
creatinine ≥200 μmol/L], stroke, bleeding history or predisposition, labile
international normalized ratio [range <60% of the time], elderly [>65],
concomitant drugs/alcohol) score aims to identify patients at high risk of
bleeding for more regular review and follow-up and draws attention to
potentially reversible bleeding risk factors.
The aim of this review article is to provide an overview of recent advances in
the understanding and management of AF with a focus on stroke prevention.
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Introduction
Atrial fibrillation (AF) is associated with a five-fold increase in the 
risk of stroke, and AF-related stroke patients have a higher mortality 
and greater morbidity than patients with non-AF-related stroke1. 
It is anticipated that by 2030 an estimated 14–17 million patients 
will be diagnosed with this most prevalent arrhythmia within 
the European Union.
Over recent years, the need for early detection and use of appropriate 
thromboprophylaxis have proved to be central in the prevention of 
AF-related stroke, which in itself carries a higher morbidity and mor-
tality than non-AF-related stroke2. The use of oral anticoagulation 
(OAC), whether with the vitamin K antagonists (VKAs, e.g. war-
farin) or, more recently, the non-VKA OACs (NOACs), results 
in a marked reduction in stroke and all-cause mortality3,4. Many 
guidelines now emphasize that the default should be to offer throm-
boprophylaxis to all patients with AF, unless “truly low risk” is 
evident such that OAC confers no advantage5. Aspirin has been 
proven to offer little net clinical benefit and is not recommended for 
stroke prevention in AF6.
Various systemic reviews have highlighted the common 
risk factors associated with AF-related stroke1,7. There are a 
number of independent “stroke risk factors”, but each may not 
necessarily contribute equally to stroke risk in AF. To aid in the 
practical evaluation of stroke risk in AF, various risk stratification 
schemes have been proposed to aid decision-making regarding 
thromboprophylaxis8. Such schemes are based on risk factors 
derived from the non-VKA arms of the historical clinical trial 
cohorts, large observational studies, and consensus opinion, and 
the resulting schemas vary greatly in their complexity and number 
of risk factors9. Even one stroke risk factor confers excess risk of 
stroke and mortality. In essence, patients with risk factors should 
be offered OAC unless contraindicated, given the positive net 
clinical benefit for treating such patients6,10,11.
The aim of this review article is to provide an overview of the recent 
advances in the diagnosis and management of patients with AF with 
a focus on stroke prevention.
Pathophysiology of atrial fibrillation and its 
complications: a brief overview
External stressors such as hypertension, diabetes mellitus, and 
AF itself can stimulate a process of atrial remodeling and subse-
quent fibrosis, which acts as a substrate for AF (along with other 
cardiac arrhythmias)12. The structural remodeling that takes place 
leads to an alteration in the electrical conduction pathway in the 
atrium, leading to a low threshold re-entry circuit and propagation 
of arrhythmias13. AF itself takes place after the process of cardiac 
remodeling and fibrosis. Thus, treatment aimed at minimizing this 
adverse remodeling pathway should be initiated at the earliest 
opportunity14.
The rhythm of AF itself along with the structural remodeling that 
takes place predisposes the atrial myocardium to a prothrombotic 
state (especially within the left atrial appendage)15. Furthermore, 
short episodes of AF can cause myocardial damage within the 
atrium, which in turn stimulates the release of prothrombotic factors 
onto the endothelial surface, leading to the aggregation of platelets. 
This, in part, explains why even short episodes of AF can confer 
long-term stroke risk16,17.
The mechanisms that cause AF are heterogeneous. For exam-
ple, in patients with structural heart disease, there is a prolonged 
atrial refractory period that acts as the substrate to AF, whereas 
patients who develop AF in the absence of ischemic heart disease 
often have a shortening of the atrial refractory period due to the 
downregulation of inward calcium channels and the upregulation 
of potassium inward currents18,19. This alteration in calcium 
handling by the atrial myocardium in line with atrial remodeling 
appears to be the most plausible explanation of how changes in 
autonomic tone can initiate AF20.
Screening for atrial fibrillation
The adverse outcomes associated with AF are preventable by the 
appropriate and timely introduction of medical therapy. Given the 
fact that AF-related stroke carries with it a poorer outcome than 
does non-AF-related stroke, the appropriate use of OACs provides 
a means by which the detrimental thromboembolic effects of AF 
can be avoided.
In an ideal setting, AF would be negated by the introduction of 
effective primary preventative therapies, with the next best option 
being the early initiation of treatment if and when AF is detected. 
However, with 30% of AF being found in asymptomatic patients, 
how best to detect this arrhythmia is of some growing concern21. 
A proportion of patients are fortunate enough to have AF detected 
by chance, often because of routine medical examinations for other 
reasons.
The absence of symptoms does not remove or reduce the risk of 
associated stroke, with this cohort of patients often found to have 
a higher CHA2DS2VASc (congestive heart failure, hypertension, 
age 65–74/>75, diabetes mellitus, stroke/transient ischemic attack 
[TIA]/thromboembolism, vascular disease, female sex) score 
than symptomatic patients22. Unfortunately, for the vast majority 
of patients with asymptomatic AF, the first opportunity to detect 
this arrhythmia is in the context of an acute stroke2. One in five 
ischemic strokes are attributable to AF, of which greater than 20% 
represent AF diagnosed after the stroke event23. Without question, 
such events could have been avoided with earlier detection and 
initiation of OAC.
The suggestion of widespread screening for AF is not new, with 
previous studies within community healthcare practices and meta-
analyses showing a clear benefit24. However, the optimal method by 
which to go about detecting asymptomatic AF is unclear.
The cryptogenic stroke and underlying AF (CRYSTAL AF) study 
was designed to evaluate whether continuous cardiac monitoring in 
the way of an implantable cardiac monitor was superior to detecting 
AF versus “conventional follow-up” in patients with a cryptogenic 
stroke or TIA25. During the 3-year study period, 447 patients were 
enrolled into this study. Of the 221 patients receiving an implant-
able cardiac monitor, 8.9% had AF detected at 6 months versus only 
1.4% in the control group. Importantly, the benefit of prolonged 
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monitoring was maintained at 12-month follow-up, with a 12.4% 
AF detection rate in the implantable cardiac monitoring group. Most 
poignantly, ischemic stroke or TIA occurred in 11 patients with the 
intracardiac monitor versus 18 patients in the control group. This 
favorable outlook in the intracardiac monitor group corresponded 
to a higher use of OACs at the 6-month interval (10.1% versus only 
4.6% in the control group).
The EMBRACE trial was another randomized controlled trial 
aimed at quantifying the benefit of longer monitoring periods for 
patients with potential AF in the context of secondary prevention of 
stroke26. Of the 572 patients enrolled, 16.2% of patients had at least 
30 seconds of AF detected over 90 days of monitoring compared 
to only 3.2% in those who underwent 24-hour monitoring. This 
correlated with an absolute difference of OAC uptake of 7.5% in 
favor of prolonged monitoring.
Recently, the SEARCH AF study analyzed the feasibility and 
cost-effectiveness of opportunistic, community-based screening 
in Australia in patients aged over 6522. A structured screen-
ing method including a brief history and pulse palpation, and a 
handheld phone-based ECG recording was taken. A total of 1000 
pharmacy customers were screened with newly identified AF in 
1.5% of the cohort. The sensitivity and specificity for this auto-
mated iECG algorithm was 98.5% and 91.4%, respectively. A 
cost-effective analysis showed that most benefit was observed in 
relation to quality-adjusted life years in those patients in whom 
anticoagulation adherence was optimal.
With the fruition of large randomized studies showing a clear ben-
efit for prolonged monitoring in patients at risk of AF along with a 
cost benefit, guidelines will no doubt begin to incorporate a more 
structured approach for the detection of asymptomatic AF. At 
present, pulse palpation and ECG rhythm strip are recommended for 
primary prevention and short-term monitoring of at least 72 hours 
in those patients having suffered a TIA or ischemic stroke5.
How much atrial fibrillation is significant?
For a long time, evidence-based guidelines have questioned whether 
“AF burden” is relevant to stroke risk. As such, current guidelines 
do not distinguish between types of AF with regard to thrombo-
prophylaxis, as observational data suggest that stroke risk is similar 
regardless of AF subtype in the presence of stroke risk factors27,28. 
The European Atrial Fibrillation Trial (EAFT) with a follow-up of 
594 patient-years found AF duration >1 year was an independent 
risk factor for secondary stroke29.
One meta-analysis examined stroke rates in 134,847 patients with 
paroxysmal AF (PAF) versus permanent AF off anticoagulation 
and reported an odds ratio (OR) of 0.75 (95% confidence interval 
[CI] 0.61–0.93) in favor of less stroke risk in patients with PAF30. 
In anticoagulated patients, the OR also favored patients with PAF 
(OR 0.77, 95% CI 0.68–0.88). This was confirmed in a further 
systematic review and meta-analysis31.
Furthermore, analysis of data from “The AF Clopidogrel Trial 
with Irbesartan for prevention of vascular events” (ACTIVE-A) 
and “Apixaban Versus Acetylsalicylic Acid to Prevent Stroke in 
AF Patients Who Have Failed or Are Unsuitable for VKA Treat-
ment” (AVERROES) trials also pointed to the idea that a pattern of 
AF was a strong independent predictor of stroke risk, second only 
to previous TIA or stroke32. In the 6,563 patients included in this 
analysis, permanent AF had an annual stroke risk of 4.2% compared 
to 2.1% with PAF and 3.0% with persistent AF. Hazard ratios of 
1.83 for permanent AF versus PAF and 1.44 for persistent AF ver-
sus PAF were found, respectively. A subanalysis of the “Rivaroxa-
ban Once daily oral direct factor Xa inhibition compared with VKA 
for prevention of stroke and Embolism Trial in AF” (ROCKET AF) 
also found that anticoagulated patients with persistent AF (11,548 
patients) were at higher risk of stroke versus those with PAF 
(2,514 patients)33. Patients with persistent AF had higher rates of 
stroke and all-cause mortality (adjusted rates for stroke 2.18 versus 
1.73 events/100 patient-years, p=0.048).
Despite trials showing that the pattern of AF has an impact on 
stroke risk, there appears to be marked heterogeneity amongst the 
respective trials, making comparisons difficult. Furthermore, the 
fluctuations in OAC use between trials makes conclusive links 
between patterns of AF and stroke risk difficult to extrapolate. 
Within types of AF, there can be marked heterogeneity. In PAF, for 
example, those with one paroxysm once a year are labeled as PAF, 
as would a patient with paroxysms of AF 364 days per year.
Therefore, at present, patients diagnosed with AF, regardless of 
type or duration, require assessment for stroke and bleeding risk 
using guideline recommendations5,34.
Anticoagulation in patients with atrial fibrillation
Stroke prevention in patients with non-valvular AF requires 
careful consideration of the risk versus benefit of starting OAC 
therapy. Stroke and bleeding risk factors in patients with AF are 
not homogeneous, and risk stratification schemes such as the 
CHA2DS2VASc and HAS BLED (hypertension systolic blood 
pressure >160 mmHg, abnormal liver/renal function [with cre-
atinine ≥200 μmol/L], stroke, bleeding history or predisposi-
tion, labile international normalized ratio [INR] [eg. Time in 
Therapeutic Range <60%], elderly >65, concomitant drugs/alcohol) 
scores are well validated and provide a simple and quick yet concise 
method of assessing a patient’s suitability for anticoagulation 
without the necessity of complex composite scores or multiple 
biomarkers8,35.
For more than 50 years, the VKAs, e.g. warfarin, have been the 
mainstay of anticoagulation in patients with non-valvular AF, 
significantly reducing stroke and mortality36. Aspirin mono-
therapy, on the other hand, is ineffective for stroke prevention and 
indeed unsafe6.
In 2009 came the introduction of the NOACs, which revolutionized 
the management of stroke prevention in non-valvular AF. Initially 
referred to as new or novel OACs, or sometimes direct OACs 
(DOACs), the NOAC acronym has been retained to refer to non-
VKA OACs37,38. The four major drugs (dabigatran, apixaban, rivar-
oxaban, and edoxaban) compare favorably with warfarin, show-
ing at least non-inferiority in regards to stroke prevention, with a 
superior safety profile with regard to major bleeding39–42. Recent 
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data from ancillary analyses of the major trials show that patients 
taking NOACs are at 30–50% lower risk of major bleeding than 
with warfarin43–45. As yet, no head-to-head trials amongst the 
NOACs have been undertaken.
Dabigatran
Dabigatran is an oral direct thrombin inhibitor, binding to the 
active catalytic site of thrombin in a reversible manner. This 
action blocks the conversion of fibrinogen to fibrin. Dabigatran is 
available as a non-active pro-drug that is converted to its active form 
in vivo (gut mucosa, liver, and plasma). Renal elimination is the 
dominant pathway of excretion for this anticoagulant (up to 80%).
The efficacy and safety of dabigatran was first evaluated in a large 
randomized controlled study in 2009. The RE-LY study compared 
dabigatran (150 and 110 mg bis die [b.d.]) to dose-adjusted warfarin. 
Efficacy analysis showed non-inferiority of the 110 mg b.d. dose 
(1.54%/year) and superiority of the 150 mg b.d. dose (1.11%/year) 
compared to warfarin (1.71%/year) for the prevention of stroke 
and systemic embolism39,46. Both dosing regimens were associated 
with lower risk of intracranial hemorrhage (ICH) compared to 
warfarin39,46. This was consistent across a range of stroke risk strata47. 
Of note, however, was the higher gastrointestinal bleeding risk with 
dabigatran 150 mg b.d. (1.51% versus 1.02%/year for warfarin)39. 
Dabigatran 150 mg b.d. was associated with a lower cardiovascular 
mortality39,46, which has been confirmed in a recent meta-analysis 
of observational data48. Since the RE-LY trial, subsequent “real 
world” evidence has provided further supportive evidence for the 
superiority of dabigatran over warfarin49–51.
Apixaban
Apixaban is a factor Xa inhibitor that is approved for patients with 
non-valvular AF in need of stroke prevention. Major trials excluded 
patients with a creatinine level of 2.5 mm/dL or a creatinine 
clearance of <25 mL/min/1.73 m2. A dose reduction is available 
from 5 mg b.d. to 2.5 mg b.d. for patients who have two of the 
following factors: age ≥80 years, weight <60 kg, or serum 
creatinine >1.5 mg/dL52,53.
In 2011, the AVERROES trial showed a clear benefit of apixaban 
over aspirin54,55. There were no significant differences in the risk 
of major bleeding or ICH between apixaban and aspirin. In 2012, 
the ARISTOTLE (apixaban for the reduction in stroke and other 
thrombotic events in atrial fibrillation) trial compared apixaban to 
warfarin in 18,201 patients41 and found apixaban to be superior to 
warfarin for the primary outcome of stroke and systemic embolism 
(1.27% versus 1.6%, respectively). Apixaban was also associated 
with a significantly lower incidence of major bleeding, ICH, and 
mortality56. In recent observational data, apixaban has been shown 
to provide greater treatment persistence versus warfarin in AF 
patients, which in itself could lead to fewer cardioembolic events 
and stroke burden57.
Rivaroxaban
The ROCKET AF trial enrolled 14,262 patients at moderate to 
high risk of stroke to either warfarin (target INR 2–3 or rivaroxa-
ban 20 mg, with a dose reduction to 15 mg in those with creati-
nine clearance of 30–49 mL/min)40. Rivaroxaban was non-inferior 
to warfarin for the composite end point of stroke and systemic 
embolism, with similar rates of major bleeding and ICH, but 
rivaroxaban had a higher incidence of gastrointestinal bleeding 
compared to warfarin. Prospective, non-interventional registries 
have provided reassuring data for rivaroxaban compared to VKAs, 
along with better treatment compliance58,59.
Edoxaban
Like apixaban and rivaroxaban, edoxaban is a selective factor Xa 
inhibitor and was tested in the phase III ENGAGE AF TIMI-48 
trial, which enrolled 21,105 patients to the high-dose edoxaban 
strategy arm, the low-dose strategy arm, or warfarin42. The high-
dose edoxaban arm was not inferior to warfarin for the primary 
endpoint of stroke and systemic embolism, with a significant 
reduction in major bleeding and ICH, although there were more 
gastrointestinal bleeds with edoxaban 60 mg versus warfarin. Effi-
cacy appeared to diminish in patients with a high creatinine clear-
ance, with edoxaban 60 mg once daily having a trend towards 
higher strokes with creatinine clearance of ≥95 mL/min, leading 
to a US Food and Drug Administration (FDA) black box for use in 
such patients. “Real world data” for edoxaban are limited, although 
indirect comparisons of edoxaban to anti-platelet therapies or 
placebo have been published60.
Reversal agents
There remain concerns regarding the bleeding risk with the 
NOACs and – until recently – the lack of a specific antidote61. 
With the introduction of idarucizumab (a fully humanized antibody 
fragment) recently licensed for use in patients taking dabigatran, 
such concerns may be unwarranted62–64. In addition, andexanet alfa 
(a truncated form of enzymatically inactive factor Xa which binds 
factor Xa inhibitors and reverses their anticoagulant effects) was 
investigated for the reversal of oral factor Xa inhibitors65. Also 
under development is ciraparantag66, which is at an earlier stage of 
development as a universal reversal agent for all NOACs.
Practical issues
As part of the initiation of NOAC therapy, the involvement of 
patient education is of central importance67,68. The patient must 
be made aware that missing a dose of NOAC potentially removes 
the stroke protection due to their relatively short half-life versus 
that of VKAs. Guidelines also emphasize the need for patient 
education and involvement in decision-making when deciding 
on the most appropriate anticoagulation5. Thus, NOACs provide 
a better, safer, and more convenient anticoagulation option with 
a greater net clinical benefit69. Accordingly, NOACs are now a 
well-established option (in addition to warfarin) for the 
prevention of thromboembolic events in non-valvular AF and 
venous thromboembolism and are given preference over warfarin in 
many updated clinical guidelines on the management of AF5,34,70.
How do clinical trial results compare with “real world 
data”?
Clinical trial data are not always reproducible in everyday 
clinical practice. Reassuringly, NOACs have continued to show a 
net clinical benefit when introduced in “real world” clinical set-
tings, with the real world observational evidence being complemen-
tary and supportive of the trial results.
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Dabigatran has been licensed and available the longest, hence 
many comparisons to warfarin in real world studies are with this 
direct thrombin inhibitor71. The real world results for dabigat-
ran have largely echoed the clinical trial findings72. In a large US 
database compromising 12,793 patients with a mean age of 74 
years, dabigatran was superior to warfarin with regard to stroke 
prevention (adjusted hazard ratio 0.73, 95% CI 0.55–0.97) with a 
lower incidence of major bleeding (adjusted hazard ratio for intrac-
ranial bleeding 0.49 [0.3–0.79])73. Other registry data have shown 
similar findings49,74. A recent meta-analysis of these observational 
data (with over 20 studies, totaling 711,298 patients) found a lower 
risk of ischemic stroke compared to warfarin (hazard ratio 0.86, CI 
0.74–0.99) with a lower incidence of intracranial bleeding (0.45, 
CI 0.38–0.52) but higher risk of gastrointestinal bleeding (1.13, CI 
1.00–1.28)51.
Real world data regarding rivaroxaban and apixaban have 
recently also gathered pace. The XANTUS observational study 
was a prospective, observational study of patients treated with 
rivaroxaban for stroke prevention in AF. A total of 6,784 patients 
were initiated on rivaroxaban across 311 centers in Europe, Israel, 
and Canada. Rates of stroke were found to be low in this cohort of 
patients, with 43 patients suffering a stroke and 43 a major bleed 
(0.7 events per 100 patient-years and 2.1 events per 100 patient-
years, respectively)75. More recently, Coleman et al. compared 
data for AF patients newly started on rivaroxaban, apixaban, or 
warfarin76. When compared to warfarin, rivaroxaban was asso-
ciated with a reduction in ICH (0.49% versus 0.96% per year, 
hazard ratio 0.53, CI 0.35–0.79), with a non-significant reduction 
in ischemic stroke (0.54% versus 0.83% per year, hazard ratio 0.71, 
CI 0.47–1.07).
The current industry-funded GARFIELD AF registry aims to recruit 
between 55,000 and 60,000 patients with AF, analyzing trends 
of anticoagulant use in patients with AF. In the fourth cohort of 
GARFIELD AF, more than 70% of AF patients are anticoagulated, 
with a growing proportion being initiated on NOAC therapy over 
warfarin (37%), and OAC use was associated with a 35% lower 
risk of death77. Other registry data have since been published for 
comparative effectiveness and safety data for dabigatran, rivaroxa-
ban, apixaban, and warfarin50,78,79.
What does the future hold for non-vitamin K antagonist 
oral anticoagulation and stroke prevention?
With the superior net clinical benefit of NOACs over VKAs, the 
opportunity to offer anticoagulation to a wider spectrum of AF 
patients is clearly evident. Previously, with the use of warfarin, 
the inconvenience of multiple blood tests for INR monitoring 
and food/drug interactions meant not all eligible patients would 
accept or be offered OAC for stroke prophylaxis. With the need for 
minimal monitoring in regards to blood tests and a reduction in 
major bleeding risk, older and arguably frailer populations who 
have AF will now have the benefit of stroke prophylaxis without 
increasing their major bleeding risk to unacceptable levels. At 
present, patients with mechanical prosthetic heart valves are not 
eligible for NOAC therapy.
What do we do for patients not suitable for OAC?
In a minority of cases, OAC may be absolutely contraindicated 
despite patients being at high risk of AF-related stroke. Aspirin is 
no longer recommended for stroke prophylaxis in patients with AF 
owing to its inferior efficacy in stroke prophylaxis along with an 
unacceptable heightened bleeding risk6. After careful considera-
tion by a multidisciplinary team and discussion with the patient, 
alternative interventions need to be sought.
Recent trial evidence has focused on the feasibility of left atrial 
appendage (LAA) closure devices. The PROTECT-AF trial 
compared the LAA device Watchman to warfarin in a randomized 
multi-center study of 707 patients, where patients were assigned in 
a 2:1 fashion to either LAA closure device with discontinuation of 
warfarin or warfarin with an INR target of 2–380. Primary end point 
data (stroke, cardiovascular death, and systemic embolization) 
showed non-inferiority of the Watchman device over warfarin 
(event rate 3 per 100 patient-years in the intervention group versus 
4.9 per 100 patient-years in the warfarin-treated cohort). Primary 
safety events (major bleeding, pericardial effusion, and device 
embolization) were more frequent in the intervention group than 
in the control group (7.4% per 100 patient-years versus 4.4% per 
100 patients-years). Of note, 15% of patients in this trial remained 
on warfarin despite being in the interventional arm. At 3.8-year 
follow-up, long-term data from the PROTECT-AF trial appear 
to be consistent with initial analysis showing non-inferiority of 
Watchman to warfarin. The PREVAIL trial compared Watchman 
to warfarin in 407 high-risk patients (CHA2DS2VASc = 3.8)81. The 
primary efficacy end points of stroke (hemorrhagic and ischemic), 
systemic embolization, and cardiovascular/unexplained death were 
similar (6.4% versus 6.3%) but did not meet the criteria for non-
inferiority, meaning there was a potential for the device to be infe-
rior to standard care. A recent patient-level meta-analysis found 
lower rates of hemorrhagic stroke with the Watchman device and 
non-inferior differences in the composite end point of all-cause 
stroke or systemic embolization. Of note, ischemic stroke per se 
occurred nearly twice as often in the Watchman arm compared to 
the warfarin arm (hazard ratio 1.95, p = 0.05)82.
However, evidence also exists for improvements in quality of life83, 
reduction in late bleeding84, and economic benefit85 with the use 
of LAA closure devices. More recently, other devices in addition 
to Watchman (although not yet FDA approved) have provided 
favorable outcomes86,87.
At present, we still do not know whether OAC-ineligible patients 
benefit from LAA closure, as the present trials were not inclusive of 
such patients, or how an LAA closure device would compare against 
the NOACs. Present treatment guidelines do state non-inferiority of 
LAA closure to standard-care warfarin, but this should be treated 
with caution as more data from long-term follow-up emerge.
Conclusion
The detection and management of AF is a core component of 
stroke prevention in the AF patient population. A proposed method 
of screening and managing AF is shown in Figure 1. With an 
increasingly aging population with multiple comorbidities, the 
diagnosis of AF becomes more likely. Most guidelines advocate 
simple opportunistic pulse check in primary care practices, but 
more prolonged forms of monitoring increase the yield of AF detec-
tion. With the introduction of NOACs, there appears to be little rea-
son not to offer anticoagulation to all AF patients with one or more 
stroke risk factors, apart from those truly deemed “low risk” using 
the CHA2DS2VASc score.
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Figure 1. Proposed algorithm for the detection and management of atrial fibrillation (AF). CHA2DS2VASc, congestive heart failure, 
hypertension, age 65–74/>75, diabetes mellitus, stroke/transient ischemic attack/thromboembolism, vascular disease, female sex; ECG, 
electrocardiogram; HAS BLED, hypertension systolic blood pressure >160 mmHg, abnormal liver/renal function [with creatinine ≥200 μmol/L], 
stroke, bleeding history or predisposition, labile international normalized ratio [range <60% of the time], elderly [>65], concomitant drugs/
alcohol; NOAC, non-vitamin K antagonist oral anticoagulant; OAC, oral anticoagulant.
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